Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity NEW YORK, NY AND CAMBRIDGE, MA — MAY 18, 2022 — The nonprofit scientific research organization IAVI and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and...